Panacea’s Post

Genetic Health Service Provider, Panacea, Launches to Make Whole Exome Sequencing Accessible to Consumers Without Insurance Barriers https://lnkd.in/gPqQ9YTH Whole exome sequencing, which has been inaccessible due to narrow medical guidelines and insurance denials, analyzes every currently-known human gene in order to identify markers of disease, allowing users to proactively plan for their health [...]

🚨Attention: Parents with babies 🚨 Does your baby qualify? 👉🏻 Babies with feeding issues, problems with movement or muscle tone, or who have missed developmental milestones may benefit from genetic testing. Learn more about Project FIND-OUT, which provides free genetic counseling and testing for infants between the ages of 3-12 months, and whether your baby might be eligible. 🫶🏻 Families who participate will receive the following free services: * Meet with a genetic counselor * Report with your child’s genetic testing results * Connect with a specialist, who can help you understand next steps and potential treatment options * Participate in research 🧬 By participating in Project FIND-OUT, you will contribute to an important research study on the value of genetic testing. We hope this study will lead to the development of guidelines for physicians and health insurance companies. Having guidelines may make it easier for other families to get genetic testing in the future and a genetic diagnosis in the future. Lastly, getting children diagnosed earlier will speed up access to new treatment options, give them COMMUNITY, give them info for family planning and perhaps inspire them to participate in research for their disease. 🔗: Enroll Now - https://lnkd.in/gbTctTZ7 #ProjectFINDOUT #RareDisease #CTNNB1 #GeneticTesting COMBINEDBrain Elizabeth Rountree CTNNB1 Connect & Cure

Important resource for parents with babies. Read below and learn how you can get free genetic testing and counseling and also contribute to a study about the value of genetic testing. Please read and share! Thank you to Effie Parks from Once Upon A Gene for always sharing such important information. #genetictesting #raredisease

Our precious 5-year-old son, Deacon, has Duchenne Muscular Dystrophy. DMD is a rare and fatal genetic muscle wasting disease, without a cure. In 2023, a promising new gene therapy treatment, the first of its kind, was FDA approved for boys age 4-5... We have been fighting UnitedHealthcare Health Plans, Inc. insurance for MONTHS trying to get this approved, only to be told no. The reasoning is that is it excluded from the plan, and amendments cannot be made mid-contract. We were also asked by the insurance broker if we knew that the cost of the medication is $3.2 million dollars. Yes. We do. We also know you CANNOT put a price on a child’s chance at life. Our son deserves the BEST shot at his life. How can an insurance company take that chance away from him??? Please sign our change.org petition to raise awareness to this issue and hopefully reverse this decision. Nationwide Children's Hospital Muscular Dystrophy Association https://lnkd.in/eVSy234R

We are honored to collaborate with the CADASIL Consortium on an important webinar for people living with this rare #genetic disease, and the healthcare providers who support them, to better understand this complex landscape, gaining tools and resources to make more confident decisions about their health. Join InformedDNA’s Tricia See, Certified Genetic Counselor, as she shares her expertise and 20+ years of #genomic insight to provide useful information and practical guidance to: - Gain a foundational understanding of #GeneticTesting and #GeneticCounseling, risks and benefits, and their interwoven relationship as part of a personalized health plan - Learn step-by-step how to prepare for genetic counseling, including what to expect from results and how they impact decision making - Explore tips and strategies related to insurance coverage, #familyplanning, and how to handle delicate conversations with family members  - Have your questions answered during live Q&A with active participants If you are a patient or provider interested in attending, please click here to register: https://lnkd.in/e-u3GD7q

The pace at which science is finding cures for rare diseases is truly amazing. But the price-tags of those treatments can be staggering. This article from Bloomberg gives the headline of "Employers Don't Want to Pay for Life-Saving Cures for Rare Diseases". That's a rather disingenuous headline at best. Making the employer out as the "bad guy" here feels wrong. Does the employer have deeper pockets than the employee? Sure, probably. But if employers (and their health insurance) are suddenly on the hook for multi-million dollar treatments, that could bankrupt a small company. Or if at a big company, it would raise the cost of health insurance to prohibitive levels. What is the solution? Do we force the companies who have developed these cures to lower their costs? What about the millions of dollars they've invested in the technology? Do we force the health insurers to cover these costs? This will drastically increase the costs of health insurance for everyone. Many employers self-insure their health coverage - a $4 million dollar health claim might be all of their revenue for a year. Do we force the government to cover this cost? Where does that money come from? There is no clear answer here. While it is truly amazing that we have these life-saving treatments, we need to find a way to pay for it or it'll only be a dream. What do you think the solution is? #healthcare #pharma #pharmaceuticals #crispr #genetics #geneticmedicine #medicine #insurance #groupinsurance #benefits #employeebenefits #disease #rarediseases https://lnkd.in/eJ3udXSV

If you are interested in using genetic testing to guide medication decisions, here’s a nice article from Precision Genetics to explain insurance coverage and costs of this test. Ask your doctor today or send us a portal message if you want us to determine your out of pocket cost. https://lnkd.in/gWhFnkfB

🚩Proud of the courage my sister friend #OliviaMunn for sharing her empowering story. As a health promotion educator and researcher, I post this here on LinkedIn because Cancer is impacting younger and younger people and insurance companies and policies are made based on statistics. You must advocate to have testing covered earlier and Mamagram’s every 6 months with MRI and Ultrasound shoudl be covered for high risk patients. It is unconscionable for me to have to pay over $800 every 6 months to screne for breast cancer. 🚨If you know anyone in your family has had breast, colon, prostate, endometrial, ovarian, cervical, skin, cancer you MUST advocate to get tested before insurance “recommendation.” 🎯Having a DNA test arms you with data to advocate for your health needs in a disease focused medical model that has health disparities that impact women and under represented. While we are busy making deadlines for work, please take a break and make your mammogram appointment and colonoscopy appointments and add reminders to your calendar every year!-just like you add your work deadlines!

📃Scientific paper: Liver‐related long‐term outcomes of thiazolidinedione use in persons with type 2 diabetes Abstract: BACKGROUND & AIMS: Studies have described prominent histologic improvement in patients with nonalcoholic steatohepatitis (NASH) using thiazolidinedione (TZD); however, these were all short term with moderate sample size, no liver‐related long‐term outcomes could be noted. METHODS: This retrospective cohort study enrolled patients with newly diagnosed type 2 diabetes mellitus (T2DM) from Taiwan's National Health Insurance Research Database between 1 January 2000 and 31 December 2013. We matched TZD users and nonusers at a 1:1 ratio through propensity score matching. This study included 5095 paired TZD users and nonusers. Cox proportional hazard models were used to compare the risks of cirrhosis, hepatic decompensation, hepatic failure and all‐cause mortality between TZD users and nonusers. The Kaplan‐Meier method was used to compare the cumulative incidence of these main outcomes. RESULTS: The incidence rates of cirrhosis, hepatic decompensation, hepatic failure and all‐cause mortality during follow‐up were 0.77 vs 1.95, 1.43 vs 1.75, 0.36 vs 0.70, and 4.89 vs 3.78 per 1000 person‐years between TZD users and nonusers. The adjusted hazard ratios of cirrhosis, hepatic decompensation, hepatic failure and all‐cause mortality were 0.39 (95% confidence interval [CI]: 0.21‐0.72), 0.86 (95% CI: 0.52‐1.44), 0.46 (95% CI: 0.18‐1.17) and 1.18 (95% CI: 0.87‐1.61) respectively. CONCLUSIONS: Our study demonstrated that TZD use could significantly lower the risk of cirrhosis. In c... Continued on ES/IODE ➡️ https://etcse.fr/iwWm ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

🌟 Exciting News in the World of Health and Wellness! 🌟 We at the Digital Health Institute for Transformation (DHIT) are thrilled to share the milestone achievement of our partners, Genomics plc and MassMutual, in their innovative approach to health and wellness. Their recent collaboration has shown remarkable success, with over 70% of participants taking planned preventative actions based on personalized health insights. This partnership is a testament to the transformative power of genomics in understanding and mitigating risks for common diseases such as heart disease, diabetes, and cancer, empowering individuals to lead healthier lives. This breakthrough underscores the importance of our upcoming webinar, 'Leveraging Genetic Risk Testing for Healthier, Longer Lives. Join us to delve deeper into how genetic risk assessments are revolutionizing healthcare and insurance, providing individuals with the knowledge to make proactive health decisions. 👉 RSVP for the webinar here: https://lnkd.in/e_hiTizD #Genomics #HealthInnovation #PreventativeCare #ForHealthForLife #DHITWebinar